Keywords: NPS Pharma, Nycomed, Gattex, Teduglutide, Short bowel syndrome,

NPS Pharma soars as Gattex meets primary efficacy endpoint in Ph III study

Article | 01 February 2011

Print This

Shares of US specialty drug developer NPS Pharmaceuticals (Nasdaq: NPSP) soared 22% to $9.30 in early trading in Monday on the news ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in